TESARO Joins OCRFA as Presenting Sponsor of the 20

WALTHAM, Mass., June 29, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO ), an oncology-focused biopharmaceutical company, is proud to support the Ovarian Cancer Research Fund Alliance (OCRFA) as the Presenting Sponsor of the 2017 Ovarian Cancer National Conference, being held July 7-9 in Chicago, IL. The OCRFA National Conference is the largest and longest-running conference for women living with ovarian cancer and their caregivers, bringing together more than 400 survivors, caregivers, researchers, and advocates to hear about the latest innovations in ovarian cancer, find hope and inspiration, and support ovarian cancer awareness initiatives. 

“Our annual conference is an opportunity to provide much needed education on cutting-edge developments in diagnosis, treatment and quality of life to women with ovarian cancer and their caregivers,” said Audra Moran, President & CEO of Ovarian Cancer Research Fund Alliance. “We are excited to partner with TESARO on our flagship conference and look forward to continued collaboration in the future.”

“Driven by a deep appreciation for patient needs, TESARO is committed to not only supporting, but truly partnering with women living with ovarian cancer,” said Lonnie Moulder, CEO of TESARO. “Patients are at the center of all that we do, and we are thrilled to join forces with OCRFA to support the 2017 Ovarian Cancer National Conference and be a part of this life-changing experience for survivors and caregivers.”

For more information about the Ovarian Cancer National Conference, please visit https://conference.ocrfa.org .

About TESARO TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com , and follow us on Twitter and LinkedIn .

Investor/Media Contact: Jennifer Davis Vice President, Corporate Affairs & Investor Relations +1.781.325.1116 or jdavis@tesarobio.com